Armata Pharmaceuticals Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Deborah Birx

Algemeen directeur

US$1.4m

Totale compensatie

Percentage CEO-salaris	17.8%
Dienstverband CEO	1.3yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	4.8yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Deborah Birx's beloning veranderd ten opzichte van Armata Pharmaceuticals's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$67m
Mar 31 2024	n/a	n/a	-US$80m
Dec 31 2023	US$1m	US$252k	-US$69m

Compensatie versus markt: De totale vergoeding ($USD 1.41M ) Deborah } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 656.26K ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Deborah te vergelijken met de prestaties van het bedrijf.

CEO

Deborah Birx (67 yo)

1.3yrs

Tenure

US$1,411,908

Compensatie

Dr. Deborah L. Birx, M.D., serves as CEO & Director of Armata Pharmaceuticals, Inc. since July 11, 2023. She is Member of Palantir Federal Advisory Board at Palantir Technologies Inc. since October 2022. S...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Deborah Birx	CEO & Director	1.3yrs	US$1.41m	geen gegevens
Mina Pastagia	Chief Medical Officer	4.1yrs	US$463.75k	0.17% $ 143.5k
David House	Senior VP of Finance & Principal Financial Officer	less than a year	geen gegevens	geen gegevens
Peter Hubbard	Vice President of Operations	less than a year	geen gegevens	geen gegevens
Pierre Kyme	Chief Business Officer	less than a year	geen gegevens	0.028% $ 23.5k

0.8yrs

Gemiddelde duur

Ervaren management: Het managementteam van ARMP wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.8 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Deborah Birx	CEO & Director	1.3yrs	US$1.41m	geen gegevens
Joseph Patti	Independent Director	5.5yrs	US$86.19k	0% $ 0
Jules Haimovitz	Independent Director	3.6yrs	US$74.88k	0% $ 0
Odysseas Kostas	Independent Director	4.8yrs	US$64.19k	0% $ 0
Athena Papas	Member of C16G2 Clinical Advisory Board	no data	geen gegevens	geen gegevens
Sarah Schlesinger	Independent Director	4.8yrs	US$66.19k	0% $ 0
Todd Peterson	Independent Director	5.1yrs	US$73.19k	0% $ 0
Robin Kramer	Independent Chairman of the Board	3.9yrs	US$105.50k	0% $ 0
James Bader	Member of C16G2 Clinical Advisory Board	no data	geen gegevens	geen gegevens
Ann Griffen	Member of C16G2 Clinical Advisory Board	no data	geen gegevens	geen gegevens
Mark Wolff	Member of C16G2 Clinical Advisory Board	no data	geen gegevens	geen gegevens
Domenick Zero	Member of C16G2 Clinical Advisory Board	no data	geen gegevens	geen gegevens

4.8yrs

Gemiddelde duur

64yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ARMP wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).

Armata Pharmaceuticals Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Armata Pharmaceuticals Announces Principal Financial Officer Changes

Insufficient new directors

Armata Pharmaceuticals, Inc., Annual General Meeting, Jun 12, 2024

Armata Pharmaceuticals, Inc. Announces CFO Changes

Armata Pharmaceuticals, Inc. Announces Deborah L. Birx to Board of Directors

Armata Pharmaceuticals, Inc., Annual General Meeting, Aug 29, 2023

Recent updates

New major risk - Revenue and earnings growth

Consensus revenue estimates decrease by 32%, EPS upgraded

Armata Pharmaceuticals Announces Principal Financial Officer Changes

Second quarter 2024 earnings released: EPS: US$0.25 (vs US$0.098 loss in 2Q 2023)

Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02

Armata Pharmaceuticals, Inc. Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled Ap-Pa02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas Aeruginosa Infection

Consensus EPS estimates fall by 43%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Armata Pharmaceuticals, Inc., Annual General Meeting, Jun 12, 2024

New minor risk - Market cap size

Consensus EPS estimates fall by 52%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference

Armata Pharmaceuticals, Inc. Announces First Patient Dosed in the Phase 2A Portion of the Phase 1b/2a 'Disarm' Study of Ap-Sa02 in Adults with Bacteremia Due to Staphylococcus Aureus

Armata Pharmaceuticals, Inc. Announces CFO Changes

Consensus revenue estimates decrease by 44%, EPS upgraded

New minor risk - Revenue size

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Share price stability

Armata Pharmaceuticals, Inc. Announces Deborah L. Birx to Board of Directors

Armata Pharmaceuticals, Inc., Annual General Meeting, Aug 29, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Armata Pharmaceuticals, Inc. Announces Executive Changes

Full year 2022 earnings: EPS and revenues miss analyst expectations

Armata Pharmaceuticals, Inc. announced that it has received $30 million in funding from Innoviva Strategic Opportunities LLC

Armata Pharmaceuticals, Inc. announced that it has received $30 million in funding from Innoviva Strategic Opportunities LLC

Armata Pharmaceuticals Announces Completion of its Phase 1b/2a 'SWARM-P.a.' Study of Inhaled AP-PA02 in Cystic Fibrosis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

High number of new directors

Price target increased to US$8.00

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Armata Pharmaceuticals, Inc., Annual General Meeting, Nov 16, 2022

Price target increased to US$8.00

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Armata Pharmaceuticals Announces Clearance of IND for Prosthetic Joint Infections

Armata Pharmaceuticals Announces First Patient Dosed in Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus Aureus

Consensus forecasts updated

High number of new directors

Armata Pharmaceuticals, Inc. announced that it has received $45 million in funding from Innoviva Strategic Opportunities LLC

Armata Pharmaceuticals, Inc. Announces CFO Changes

Consensus forecasts updated

Full year 2021 earnings: EPS misses analyst expectations

Armata Pharmaceuticals, Inc. Announces Clearance of Investigational New Drug Application to Initiate Phase 2 Clinical Trial of AP-PA02 in Non-Cystic Fibrosis Bronchiectasis

Price target increased to US$8.00

Armata Pharmaceuticals Provides Update on Pseudomonas Respiratory Programs

Third quarter 2021 earnings released: US$0.22 loss per share (vs US$0.31 loss in 3Q 2020)

Consensus forecasts updated

Price target increased to US$8.00

Consensus revenue estimates fall to US$666.7k

Armata Pharmaceuticals Inc. announced that it has received $20 million in funding from Innoviva, Inc.

Analysts update estimates

New 90-day high: US$5.07

New 90-day low: US$2.83

Earnings beat expectations, revenue disappoints

New 90-day high: US$3.94

Armata Pharmaceuticals Inc. Appoints Mina Pastagia as Vice President of Clinical Development

Armata Pharmaceuticals Announces Clearance of Investigational New Drug (IND) Application to Initiate Phase 1b/2a Clinical Trial of Lead Candidate AP-PA02 in Pseudomonas aeruginosa Infections

New 90-day low - US$3.26

Armata Pharmaceuticals Inc.(AMEX:ARMP) dropped from Russell Microcap Value Index

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur